13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
57 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03807973
(ClinicalTrials.gov)
December 30, 202014/1/2019Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;HealthyDrug: [Zr-89]Oxine-labeled leukocytes PET/MRUniversity of Alabama at BirminghamNULLNot yet recruiting18 Years65 YearsAll120Phase 1NULL
2NCT04267926
(ClinicalTrials.gov)
October 6, 202011/2/2020MitoQ for Fatigue in Multiple Sclerosis (MS)MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled TrialMultiple Sclerosis;FatigueDrug: 20 mg MitoQ;Drug: Placebo;Drug: 40mg of MitoQVA Office of Research and DevelopmentNULLRecruiting18 Years70 YearsAll60Phase 1;Phase 2United States
3NCT04448977
(ClinicalTrials.gov)
October 202015/6/2020Examining Effects of Ocrevus on Cognitive Fatigue Using fMRIA Biomarker for Cognitive Fatigue Using Functional Imaging in MSMultiple Sclerosis, Relapsing-RemittingDrug: OcrevusKessler FoundationHackensack Meridian HealthNot yet recruiting18 Years64 YearsAll60United States
4NCT04565431
(ClinicalTrials.gov)
October 202025/8/2020Examining Effects of Tysabri on Cognitive Fatigue Using fMRIBiomarker for Cognitive Fatigue Using Functional Imaging in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: TysabriKessler FoundationSt. Barnabas Medical CenterNot yet recruiting18 Years64 YearsAll25United States
5NCT03983720
(ClinicalTrials.gov)
January 21, 20207/6/2019Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?Sclerosis, MultipleOther: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluationCentre Hospitalier Universitaire de Saint EtienneNULLRecruiting18 Years70 YearsAll60Phase 2France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03910738
(ClinicalTrials.gov)
October 29, 20191/4/2019TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple SclerosisTOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disabilityUniversity Hospital, Strasbourg, FranceBayer;Fédération Hospitalo-Universitaire NEUROGENYCSRecruiting18 Years55 YearsMale40Phase 2France
7NCT04144257
(ClinicalTrials.gov)
October 201928/10/2019Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related FatigueRole of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related FatigueMultiple SclerosisDrug: [F-18]PBR06;Drug: [C-11]MethylreboxetineBrigham and Women's HospitalUnited States Department of DefenseNot yet recruiting18 Years60 YearsAll12Phase 1;Phase 2United States
8NCT04408742
(ClinicalTrials.gov)
April 15, 201926/5/2020Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple SclerosisThe Relationship Between Pain, Anxiety and Fatigue and Knee Position Sense, Balance and Dual Task Performance During Menstrual Cycle in Females With Multiple SclerosisMultiple Sclerosis;Menstrual Pain;Anxiety;Fatigue;Neurologic SymptomsOther: pain;Other: fatigue;Other: anxiety;Other: position sense;Other: balance;Other: dual task performanceAnkara Yildirim Beyazit UniversityNULLCompleted26 Years49 YearsFemale14Turkey
9NCT03759522
(ClinicalTrials.gov)
February 3, 20196/11/2018Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;HealthyDrug: DPA-714 PET/MRIUniversity of Alabama at BirminghamNULLRecruiting18 Years65 YearsAll120Phase 1United States
10NCT03621761
(ClinicalTrials.gov)
November 15, 20183/8/2018Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis FatigueA Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple SclerosisMultiple SclerosisBehavioral: Telephone-based Cognitive Behavioral Therapy;Drug: ModafinilUniversity of MichiganUniversity of Washington;Patient-Centered Outcomes Research Institute;National Multiple Sclerosis SocietyRecruiting18 YearsN/AAll330Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03166800
(ClinicalTrials.gov)
September 15, 201823/5/2017MitoQ for Fatigue in Multiple SclerosisMitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled TrialMultiple Sclerosis;FatigueDrug: MitoquinoneOregon Health and Science UniversityMitoQ LtdCompleted18 Years70 YearsAll9Phase 1;Phase 2United States
12NCT03500289
(ClinicalTrials.gov)
August 10, 20184/4/2018Ketamine for Treatment of MS FatigueKetamine for Treatment of Multiple Sclerosis-related FatigueMultiple Sclerosis;FatigueDrug: Ketamine;Drug: MidazolamJohns Hopkins UniversityNational Multiple Sclerosis SocietyCompleted18 Years65 YearsAll18Phase 1;Phase 2United States
13EUCTR2018-000721-31-SE
(EUCTR)
04/07/201824/04/2018A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis.RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MSA randomized trial of long-term dosage of rituximab in multiple sclerosisThe RIDOSE-MS trial is a multi-centre trial of long-term treatment with rituximab in MS, randomised between two different dosing regimens. Population: Patients with RRMS that has completed the RIFUND-MS trial in either the rituximab or DMF arm. In addition, patients will be recruited that has not participated in the RIFUND trial but has been treated with rituximab with the same protocol as in the RIFUND trial as part of clinical practice.Intervention: Treatment with rituximab (Mabthera®) 500 mg every six months. Both the previous rituximab and DMF arms from the RIFUND trial will be treated with rituximab in the RIDOSE trial.Control: After one year of treatment in RIDOSE-MS, patients will be randomised 1:1 to either continue with 500 mg every 6 months or 500 mg every 12 months and continue on this treatment schedule for another 3 years.Outcome: Primary outcome will be the proportion of patients remaining with no evidence of disease activity (NEDA) -3 over the randomised period of 3 years. As secondary endpoints progression of disability, brain atrophy, cognitive function and level of serum Neurofilament-Light will be evaluated. In addition, Patient-related outcome scales measuring fatigue, work ability and treatment satisfaction will be analysed. - RIDOSE-MS Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addition, patients will be recruited that has not participated in the RIFUND trial but has been treated with rituximab with the same protocol as in the RIFUND trial as part of clinical practice.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Mabthera
Product Name: Mabthera
INN or Proposed INN: RITUXIMAB
Trade Name: Mabthera
Product Name: Mabthera
INN or Proposed INN: RITUXIMAB
Department of Clinical Sciences, Karolinska Institutet Danderyd HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 2Sweden
14NCT03000127
(ClinicalTrials.gov)
July 1, 201817/12/2016Testosterone for Fatigue in Men With MSA Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple SclerosisMultiple SclerosisDrug: AndroGel 1 % Topical Gel;Drug: PlacebosUniversity of California, Los AngelesWashington University School of MedicineWithdrawn18 Years60 YearsMale0Phase 2United States
15NCT03501342
(ClinicalTrials.gov)
April 9, 201810/4/2018Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple SclerosisEffects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple SclerosisMultiple SclerosisOther: Virtual reality group;Other: Dynamic Balance TrainingGazi UniversityNULLCompleted18 Years65 YearsAll39N/ATurkey
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT03266965
(ClinicalTrials.gov)
March 23, 20184/7/2017Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachHistaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachMultiple SclerosisDrug: Carbidopa;Dietary Supplement: L-HistidineUniversity of MiamiUnited States Department of DefenseCompleted18 Years60 YearsAll18Phase 1United States
17NCT03185065
(ClinicalTrials.gov)
October 4, 20179/6/2017Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple SclerosisTreatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple SclerosisFatigue in Multiple SclerosisDrug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: PlacebosJohns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompleted18 YearsN/AAll141Phase 3United States
18EUCTR2017-001253-13-BE
(EUCTR)
23/08/201711/07/2017Does decresaed perfusion of the brain play a role in the reduced function of axons and the clinical disability and fatigue in patients with multiple sclerosis ?Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis) Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be any clinical evidence of an MS relpase within the 3 months prior to inclusion.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: TracleerUZ BrusselNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Belgium
19NCT03110315
(ClinicalTrials.gov)
March 28, 201728/3/2017A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and InsomniaA Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and InsomniaMultiple Sclerosis;Fatigue;InsomniaDrug: Suvorexant;Drug: PlaceboTheodore R. Brown, MD MPHMerck Sharp & Dohme Corp.Recruiting18 Years75 YearsAll30Phase 4United States
20NCT03164018
(ClinicalTrials.gov)
March 7, 201729/3/2017Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life AnalysisFampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life AnalysisMultiple SclerosisDrug: FampridineGenesis Pharma CNS & SpecialtyNULLCompleted18 YearsN/AAll111Greece
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03051646
(ClinicalTrials.gov)
January 13, 20178/2/2017Aspirin as a Pre-Treatment for Exercise in Multiple SclerosisA Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple SclerosisFatigue;OverheatingDrug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit;Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visitColumbia UniversityNational Multiple Sclerosis SocietyCompleted18 Years60 YearsAll12Early Phase 1United States
22NCT02804594
(ClinicalTrials.gov)
October 1, 20163/6/2016A Study of Oxidative Pathways in MS FatigueA Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple SclerosisProgressive Multiple Sclerosis;FatigueDrug: N-acetyl cysteine;Drug: PlaceboUniversity of California, San FranciscoNULLCompleted18 Years75 YearsAll15Phase 2United States
23NCT02870023
(ClinicalTrials.gov)
June 20169/8/2016How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?Multiple SclerosisOther: Balance training;Other: Strength trainingUniversity of AarhusVIA University College;TrygFonden, Denmark;Fondazione Don Carlo Gnocchi OnlusCompleted18 YearsN/AAll71N/ADenmark
24NCT02090348
(ClinicalTrials.gov)
June 201514/3/2014Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateA Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)Relapsing-Remitting Multiple Sclerosis;Multiple SclerosisDrug: dimethyl fumarateBiogenNULLWithdrawn18 YearsN/ABoth0Phase 4NULL
25NCT02315872
(ClinicalTrials.gov)
May 22, 20159/12/2014ACTH for Fatigue in Multiple Sclerosis PatientsThe Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.Multiple Sclerosis, Relapsing-RemittingDrug: ACTH;Drug: PlaceboProvidence Health & ServicesMallinckrodtCompleted18 Years65 YearsAll8Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2013-001025-53-ES
(EUCTR)
18/05/201503/03/2015A Study that evaluates Fatigue in Multiple Sclerosis Patients taking Tecfidera® (Dimethyl Fumarate)A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsule (TECNERGY) - TECNERGY Relapsing-Remitting Multiple Sclerosis
MedDRA version: 17.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Tecfidera (BG00012)
Product Name: Tecfidera
Product Code: BG00012
INN or Proposed INN: DIMETHYL FUMARATE
Other descriptive name: DIMETHYL FUMARATE
Trade Name: Tecfidera (BG00012)
Product Name: Tecfidera
Product Code: BG00012
INN or Proposed INN: DIMETHYL FUMARATE
Other descriptive name: DIMETHYL FUMARATE
Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes
320Finland;Spain;Denmark;Norway;Netherlands;United Kingdom
27NCT02391961
(ClinicalTrials.gov)
April 1, 20153/3/2015Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple SclerosisStudy and Treatment of Visual Dysfunction and Motor Fatigue in Multiple SclerosisMultiple Sclerosis;Internuclear Ophthalmoplegia;FatigueDrug: Dalfampridine;Drug: PlaceboVA Office of Research and DevelopmentNULLCompleted18 Years65 YearsAll23Phase 2United States
28EUCTR2013-001025-53-DK
(EUCTR)
05/03/201524/03/2014A Study that evaluates Fatigue in Multiple Sclerosis Patients taking Tecfidera® (Dimethyl Fumarate)A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsule - TECNERGY Relapsing-Remitting Multiple Sclerosis
MedDRA version: 17.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Tecfidera (BG00012)
Product Name: Tecfidera
Product Code: BG00012
INN or Proposed INN: DIMETHYL FUMARATE
Other descriptive name: DIMETHYL FUMARATE
Trade Name: Tecfidera (BG00012)
Product Name: Tecfidera
Product Code: BG00012
INN or Proposed INN: DIMETHYL FUMARATE
Other descriptive name: DIMETHYL FUMARATE
Biogen Idec Research LimitedNULLNot RecruitingFemale: yes
Male: yes
320Phase 4Finland;Spain;Denmark;Norway;Netherlands;United Kingdom
29NCT02286557
(ClinicalTrials.gov)
October 201416/10/2014Testing the Effects of Methylphenidate on Multiple SclerosisTesting the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical TrialFatigue in Multiple SclerosisDrug: Methelphenidate;Drug: PlaceboKessler FoundationNULLNot yet recruiting18 Years65 YearsBoth36Phase 2NULL
30NCT01766063
(ClinicalTrials.gov)
December 6, 20127/12/2012Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on BetaferonBETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS PatientsMultiple SclerosisDrug: Interferon beta-1b (Betaferon, BAY 86-5046)BayerNULLCompleted18 YearsN/AAll138Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT01720849
(ClinicalTrials.gov)
December 201231/10/2012Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple SclerosisMultiple Sclerosis;EDSS 4-7Drug: FampyraVestre Viken Hospital TrustNULLRecruiting18 YearsN/ABoth50N/ANorway
32NCT01879202
(ClinicalTrials.gov)
December 20127/11/2012Methylphenidate as Treatment Option of Fatigue in Multiple SclerosisMethylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.Multiple Sclerosis;FatigueDrug: Methylphenidate modified release;Drug: MaltodextrinMedical University of ViennaNULLRecruiting18 YearsN/ABoth96Phase 2Austria
33EUCTR2012-003418-15-AT
(EUCTR)
23/10/201209/11/2012Methylphenidate modified release as treatment of MS-associated fatigue.Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial. Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIVand parkinson´s disease, data on its efficacy in MS are not available.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Ritalin LA 20mg capsules
Product Name: Methylphenidate modified release 20 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Trade Name: Ritalin LA 30mg capsules
Product Name: Methylphenidate modified release 30 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Trade Name: Ritalin LA 40mg capsules
Product Name: Methylphenidate modified release 40 mg
INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE
Medizinische Universität WienNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Austria
34NCT01667497
(ClinicalTrials.gov)
September 201213/8/2012Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over StudyCognitive FatigueDrug: Fampridine SR;Drug: PlaceboLondon Health Sciences CentreNULLCompleted18 Years64 YearsBoth60Phase 2;Phase 3Canada
35NCT01718678
(ClinicalTrials.gov)
May 201228/10/2012Effect of Melatonin on Multiple Sclerosis Related FatigueStudy of Melatonin in Treatment of Fatigue in Multiple SclerosisFatigueDrug: Melatonin;Drug: PlaceboIsfahan University of Medical SciencesNULLCompleted18 Years55 YearsBoth44Phase 2Iran, Islamic Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01591551
(ClinicalTrials.gov)
March 201222/4/2012NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or SleepinessNAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or SleepinessMultiple Sclerosis, Relapsing-RemittingDrug: Natalizumab (Tysabri)Cornerstone Health Care, PABiogen IdecCompleted18 Years65 YearsBoth37Phase 4United States
37NCT01516554
(ClinicalTrials.gov)
February 201219/1/2012Oral Testosterone for Fatigue in Male Multiple Sclerosis PatientsA Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis PatientsMultiple Sclerosis;FatigueDrug: Testosterone undecanoate;Drug: placeboHealth Sciences Centre, Winnipeg, ManitobaUniversity of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service FoundationTerminated18 Years65 YearsMale3Phase 2Canada
38EUCTR2011-002969-38-DE
(EUCTR)
08/11/201130/09/2011A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phaseA 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase - Fatigue in Patients with relapsing remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Gilenya
Product Name: Fingolimod
Product Code: FTY720
Other descriptive name: Fingolimod Hydrochloride
Novartis Pharma GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase AGermany
39EUCTR2010-023678-38-IT
(EUCTR)
20/04/201102/02/2011High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - NDHigh-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND patients with multiple sclerosis
MedDRA version: 9.1;Level: PT;Classification code 10028245
Trade Name: MANTADAN*20CPR 100MG
INN or Proposed INN: Amantadine
Trade Name: AMPYRA
INN or Proposed INN: Ampyra
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABORNULLNot RecruitingFemale: yes
Male: yes
Italy
40EUCTR2011-000150-31-IT
(EUCTR)
13/04/201128/12/2011EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY.EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. Multiple Sclerosis patients
MedDRA version: 14.1;Level: HLGT;Classification code 10012303;Term: Demyelinating disorders;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 14.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: COPAXONE
INN or Proposed INN: Glatiramer acetate
FONDAZIONE DON CARLO GNOCCHI ONLUSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT01712373
(ClinicalTrials.gov)
December 201019/10/2012Ginseng in Treatment of Fatigue in Multiple SclerosisStudy of Ginseng in Treatment of Fatigue in Multiple SclerosisFatigueDrug: Ginseng;Drug: PlaceboIsfahan University of Medical SciencesNULLCompleted18 Years50 YearsBoth60Phase 2Iran, Islamic Republic of
42NCT01149525
(ClinicalTrials.gov)
June 201021/6/2010Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple SclerosisA Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple SclerosisMultiple SclerosisDrug: L-Carnitine;Drug: PlaceboUniversity Hospital, BordeauxNULLCompleted18 YearsN/AAll59Phase 3France
43NCT01354665
(ClinicalTrials.gov)
May 201016/5/2011Depression and Fatigue in MS Patients Treated With Betaferon.The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.Multiple SclerosisBiological: Interferon beta-1b (Betaferon, BAY86-5046)BayerNULLCompleted18 YearsN/ABoth567N/APoland
44EUCTR2009-015934-30-FR
(EUCTR)
02/02/201019/01/2010étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEPétude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP sclérose en plaquefatigue
MedDRA version: 12.0;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: levocarnil
Product Name: Levocarnil
Product Code: na
INN or Proposed INN: L-carnitine
CHU de BordeauxNULLNot RecruitingFemale: yes
Male: yes
Phase 3France
45NCT00981084
(ClinicalTrials.gov)
September 200918/9/2009Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover StudyMultiple SclerosisDrug: armodafinilUniversity of Missouri, Kansas CityUniversity of KansasCompleted18 Years60 YearsAll33Phase 2;Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01075880
(ClinicalTrials.gov)
May 200924/2/2010Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With RebifMultiple Sclerosis, Relapsing-RemittingDrug: Rebif (Interferon beta-1a)Merck KGaAMerck spol.s.r.o., Czech RepublicCompleted18 Years65 YearsBoth300N/ACzech Republic
47NCT00884481
(ClinicalTrials.gov)
March 23, 200917/4/2009Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSA Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 MonthsRelapsing-Remitting Multiple Sclerosis;FatigueOther: NatalizumabBiogenNULLCompleted18 Years65 YearsAll195Austria;Denmark;Norway;Sweden;United States
48EUCTR2008-008065-35-SE
(EUCTR)
13/03/200917/12/2008A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the course of 12 months - TYNERGY Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
MedDRA version: 9.1;Classification code 10016256;Term: Fatigue
Trade Name: TysabriBiogenIdec A/SNULLNot RecruitingFemale: yes
Male: yes
200Sweden
49NCT00467584
(ClinicalTrials.gov)
July 200726/4/2007Aspirin for Treatment of Multiple Sclerosis-Related FatigueAspirin for Treatment of Multiple Sclerosis-Related FatigueMultiple Sclerosis;FatigueDrug: High Dose Aspirin (1300 mg/day);Drug: Low Dose Aspirin (162 mg/day);Drug: PlaceboMayo ClinicNational Multiple Sclerosis SocietyTerminated18 Years65 YearsAll62Phase 3United States
50NCT00594087
(ClinicalTrials.gov)
December 20063/1/2008Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime FatigueRelapsing Remitting Multiple Sclerosis;Sleep Initiation and Maintenance Disorders;FatigueDrug: eszopiclone;Other: placeboUniversity of VermontNULLCompleted18 Years64 YearsBoth30N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT00882453
(ClinicalTrials.gov)
August 200615/4/2009Physical Activity and Fatigue in Early Multiple Sclerosis (MS)Betaferon Treatment and Exercise Data Gathering IN Early MSMultiple SclerosisDrug: Interferon beta-1b (Betaseron, BAY86-5046)BayerNULLCompleted18 YearsN/ABoth1739N/AAustralia;Austria;Bahrain;Belgium;Canada;Colombia;Czech Republic;Denmark;Egypt;France;Germany;Greece;Indonesia;Israel;Italy;Jordan;Kazakhstan;Korea, Republic of;Kuwait;Lebanon;Mexico;Netherlands;Norway;Oman;Portugal;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;United Arab Emirates;United Kingdom
52NCT00342381
(ClinicalTrials.gov)
June 200620/6/2006Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic StimulationFatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic StimulationMultiple Sclerosis;FatigueDrug: 3,4-diaminopyridine;Drug: PlaceboUniversity of AarhusThe Danish Multiple Sclerosis SocietyCompleted18 Years55 YearsBoth120Phase 2Denmark
53EUCTR2005-005211-21-FI
(EUCTR)
17/01/200607/12/2005A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 yearsA long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years Remitting relapsing multiple sclerosis (RRMS) is one of the most common diseases of the central nervous system. The cause of MS is not yet known but it is a result of damage to myelin. Symptoms vary widely and include blurred vision, weak limbs, tingling sensations, unsteadiness and fatigue.Trade Name: Betaferon
Product Name: Betaferon
INN or Proposed INN: Beta-1b interferoni
Schering OyNULLNot RecruitingFemale: yes
Male: yes
80Finland
54NCT00754832
(ClinicalTrials.gov)
September 200516/9/2008American Ginseng Treatment for Multiple Sclerosis Related FatigueA Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related FatigueMultiple SclerosisDrug: American ginseng extract HT-1001;Drug: placeboOregon Health and Science UniversityNational Multiple Sclerosis SocietyCompleted18 Years70 YearsAll56Phase 2United States
55NCT00220506
(ClinicalTrials.gov)
September 200514/9/2005Fatigue Treatment Using ProvigilFatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple SclerosisAll Multiple Sclerosis PatientsDrug: ProvigilSheba Medical CenterNULLRecruiting18 Years55 YearsBoth50N/AIsrael
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT00190268
(ClinicalTrials.gov)
February 200513/9/2005Efficacy of 3,4-DAP in Fatigue Associated With Multiple SclerosisMulticentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple SclerosisMultiple SclerosisDrug: 3,4-diaminopyridineAssistance Publique - Hôpitaux de ParisNULLCompleted18 Years60 YearsBoth126Phase 3France
57NCT00267319
(ClinicalTrials.gov)
June 200319/12/2005FOCUS Fatigue Outcome in Copaxone USersFatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple SclerosisMultiple SclerosisDrug: Glatiramer acetateSanofiNULLCompleted18 YearsN/ABoth111Phase 4Czech Republic